Physician profile
Robert Oertli
NPI 1639150378
$1,860.60
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $775 · 2021: $283 · 2022: $41.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.28 | 2019-2021 | |
| Abbvie INC. | $189.12 | 2021-2022 | |
| Pfizer INC. | $181.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $162.44 | 2019-2020 | |
| Lilly USA, LLC | $139.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $137.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $118.25 | 2019-2022 | |
| Amgen INC. | $82.84 | 2019-2020 | |
| Allergan, INC. | $81.31 | 2019-2020 | |
| Amarin Pharma, INC. | $80.28 | 2019-2020 | |
| Astellas Pharma US INC | $67.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.31 | 2019-2020 | |
| Sanofi Pasteur INC. | $47.39 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.36 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.57 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2021 | |
| Abbott Laboratories | $13.53 | 2019 | |
| Dexcom, INC. | $12.74 | 2021 | |
| Glaxosmithkline, LLC. | $11.77 | 2020 | |
| Neuronetics, INC. | $10.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oertli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.